Edesa Biotech, INC

Edesa Biotech announced a $3.5 million private placement financing, including participation from its CEO, to advance its vitiligo program and for general corporate purposes.

Edesa Biotech announced favorable exploratory clinical data for paridiprubart in patients with acute kidney injury and respiratory distress.

Edesa Biotech's CEO will receive 90% of his base salary in restricted stock units, a significant increase from the previous 50% equity component.

Edesa Biotech announced its fiscal second quarter 2026 financial results, highlighting progress in its dermatology and respiratory programs, with a focus on upcoming clinical studies.

Edesa Biotech announced positive additional data from its Phase 3 study of paridiprubart, demonstrating a statistically significant reduction in 28-day mortality across a broader patient population.

Edesa Biotech, Inc. increased its at-the-market offering capacity to $2,262,508 for common shares, signaling continued capital raising efforts.

Edesa Biotech reports a significant increase in R&D expenses for Q2 2026, driven by preparations for clinical trials, while net loss widens compared to the prior year period.

Edesa Biotech reported an increased net loss in Q1 2026 but ended the quarter with a stronger cash position, driven by recent equity raises and progress in its clinical programs for vitiligo and ARDS.

Edesa Biotech reports a net loss of $1.7 million, or $0.25 per common share, for Q3 2025, with a focus on advancing its vitiligo program.

Edesa Biotech reports a net loss of $3.2 million for the six months ended March 31, 2025, and provides an update on its clinical programs and recent financing activities.

Edesa Biotech reports a net loss of $1.6 million for the quarter ended December 31, 2024, and highlights recent financing activities to support ongoing clinical programs.

Edesa Biotech's Q3 2024 results show a reduced net loss compared to the previous year, alongside progress in clinical trials and government funding.

Edesa Biotech announced positive Phase 3 results for its ARDS drug candidate EB05 and secured significant equity financing, but faces ongoing losses and a going concern warning.

Edesa Biotech has filed an amendment to its annual report to include an additional shareholder owning more than 5% of the company's common shares.

Edesa Biotech's annual report highlights a strategic shift towards general ARDS research and development, alongside ongoing efforts in dermatology and pulmonary fibrosis.

Pardeep Nijhawan, CEO and Director of Edesa Biotech, acquired 3,378 restricted share units on July 2, 2026, as part of the company's equity incentive plan.

Edesa Biotech CEO Pardeep Nijhawan acquired 153,550 common shares in a private placement transaction valued at approximately $800,000.

Edesa Biotech CEO Pardeep Nijhawan acquired 1,671 common shares through a restricted share unit grant that vested immediately.

Director Patrick Marshall was granted 19,000 restricted share units in Edesa Biotech, Inc. as part of the company's 2019 Equity Incentive Compensation Plan.

Director Sean Arthur MacDonald was granted 19,000 restricted share units in Edesa Biotech, Inc. as part of the company's 2019 Equity Incentive Compensation Plan.

Director Joan Chypyha was granted 19,000 restricted share units in Edesa Biotech, Inc. as part of the company's 2019 Equity Incentive Compensation Plan.

Edesa Biotech, Inc. has issued its proxy statement detailing the agenda for its 2026 Annual General and Special Meeting of Shareholders, including director elections and equity plan amendments.

Edesa Biotech, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Edesa Biotech is asking shareholders to approve an amendment to its 2019 Equity Incentive Compensation Plan to increase the number of shares available for issuance, remove fungible share pool provisions, and increase the number of shares issuable as incentive stock options.

Edesa Biotech, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Edesa Biotech's upcoming annual meeting on May 30, 2024, will address the election of directors, executive compensation, an equity incentive plan amendment, and the appointment of auditors.

Dr. Pardeep Nijhawan has increased his beneficial ownership in Edesa Biotech to 19.99% following a private placement and open market purchases.

Velan Capital and its affiliates have increased their beneficial ownership in Edesa Biotech, Inc. to 9.99% of outstanding common shares.

Dr. Pardeep Nijhawan and affiliated entities have increased their beneficial ownership in Edesa Biotech, Inc. to 19.99% through recent share purchases and RSU grants.

Velan Capital and its affiliated entities have acquired a 9.99% beneficial ownership stake in Edesa Biotech, Inc. through a private placement, gaining a board seat and observer rights, citing the company's shares as undervalued.

Dr. Pardeep Nijhawan and affiliated entities have increased their beneficial ownership in Edesa Biotech, Inc. to 19.99% through recent restricted share unit grants and a private placement of Series B-1 Convertible Preferred Shares.

Several entities affiliated with Millennium Management have reported a combined beneficial ownership of 5.4% of Edesa Biotech's common shares.

Stonepine Capital Management has filed a Schedule 13G reporting a 0.3% beneficial ownership stake in Edesa Biotech, Inc.

Nantahala Capital Management and its principals have filed an amendment indicating they no longer hold any beneficial ownership in Edesa Biotech.

Point72 Asset Management, L.P. and Steven A. Cohen disclose a beneficial ownership of 2 common shares in Edesa Biotech, Inc.

Rubric Capital Management LP and David Rosen have reported a 7.74% beneficial ownership stake in Edesa Biotech, Inc. via a Schedule 13G filing.

Sirenia Capital Management LP and Alex Silverstein jointly report a 7.2% stake in Edesa Biotech, Inc. as of March 31, 2026.